Dare Bioscience looks set for a run, with two products in its pipeline, and the current weakness looks like the final crunch. Having just completed an offering, it should not let a delisting happen despite a market cap of about $13M. x.com x.comÂ
Dare Bioscience is moving from an R&D firm toward a pharmaceutical company as it prepares to launch Flora Sync soon. The next earnings report should be fantastic. x.comÂ
